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Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is a rare B-cell malignancy associated with excellent survival.
However, some patients experience histological transformation into aggressive large B-cell lymphoma. Population-based data on
transformation in patients with NLPHL is limited. We conducted a nationwide population-based study to estimate the risk of
transformation and relative survival in patients diagnosed with NLPHL in Finland between 1995 and 2018. We identified a total of
453 patients (median age, 48 years; 76% males) with the incident NLPHL from the Finnish Cancer Registry. The cumulative
incidence of transformation was 6.3% (95% CI, 4.2-9.6) at 10 years. After adjusting for sex, age and year of diagnosis, transformation
was associated with a substantially increased risk of death (HR 8.55, 95% CI 4.49−16.3). Ten-year relative survival was 94% (95% CI,
89%‒100%). The patients diagnosed at a later calendar year had lower excess risk of death (HR, 0.38 per 10-year increase; 95% CI,
0.15‒0.98). We conclude that while the 10-year relative survival for the patients with NLPHL was excellent in this large population-
based cohort for the entire study period, transformation resulted in a substantially increased mortality compared with the patients
without transformation. Our results also suggest a reduction in excess mortality over time.
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INTRODUCTION
Worldwide, Hodgkin lymphoma (HL) accounted for an estimated 83
000 (0.4%) new cancer cases and 23 000 (0.2%) cancer deaths in
2020 [1]. While the age-standardized incidence remained rather
stable, the age-standardized mortality and disability adjusted life-
year rates have steadily decreased since the 1990s [1, 2], resulting in
excellent survival rates. For example, between 2014 and 2018 in the
Nordic countries, 5-year relative survival was over 85%. In Finland,
approximately 180 new HL cases are diagnosed annually [2, 3].
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)
is a rare subtype of HL with unique clinicopathological features,
and an estimated incidence of 1-3 per million per year,
representing 5-15% of all new HL cases [4–7]. In contrast to
classical HL (cHL), NLPHL mainly affects middle-aged males,
clinical course of the disease is generally indolent, and most
patients present with limited-stage disease at diagnosis. Also,
there is a risk of late disease progression and histological
transformation into large B-cell lymphoma [8, 9].
Population-based data on transformation in patients with
NLPHL is limited since the majority of cancer registries do not
capture transformation status. Therefore, the current literature is
mainly comprised of retrospective single-center studies. The
results regarding the impact of transformation on survival are
also inconclusive [10–14].
In comparison to cHL, NLPHL patients have better survival, and
in young adults, survival may even be comparable to the general
population [15–17]. Excess mortality is low and largely associated
with transformation to large B-cell lymphoma and treatment-
related long-term effects, such as secondary malignant neoplasms
and cardiovascular diseases [11, 18].
There are no randomized controlled trials, and only a few
prospective studies on NLPHL have been conducted to guide
treatment decisions. Historically, patients with NLPHL have
been treated similarly to cHL. However, increasing evidence
has accumulated during the last two decades to support the
use of less aggressive therapeutic approaches [19]. Patients
with limited-stage disease are usually managed with radio-
therapy or combined modality treatment, whereas systemic
treatment with combination chemotherapy is indicated for the
patients with advanced-stage disease [19]. Since NLPHL cells
express CD20, biological agents, such as rituximab, have
emerged as an additional treatment option since the early
2000s [19].
We conducted a nationwide population-based study to
estimate the risk of transformation to large B-cell lymphoma
and relative survival in patients diagnosed with NLPHL in Finland
in 1995−2018. We also compared mortality rates between
patients with or without transformation.
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The Finnish Cancer Registry (FCR) is a statistical and epidemiological
research institute responsible for registering nationwide data on all
incident cancer diagnoses in Finland since 1953. Physicians, hospitals, and
pathology and hematology laboratories are obliged to report cancer cases
to the FCR without consent of the patient based on a special legislation.
The reports include a unique personal identity code, which allows for
linkage between national registries and reliable follow-up of cancer
patients. Extensions, recurrences, metastases, or transformations of
previously recorded primary cancers are reported to the FCR but are not
registered as separate cases. Since 2007, the coding of cancer cases has
followed the International Classification of Diseases for Oncology, 3rd
Edition (ICD-O-3), which is consistent with the WHO Classification of
Tumours of Haematopoietic and Lymphoid Tissues, 4th edition [4, 20]. In
1953–2006, cancer morphology was coded according to a slightly modified
version of the Manual of Tumor Nomenclature and Coding and
topography according to the International Classification of Diseases, 7th
revision. In 2007, former codes were converted to ICD-O-3 [21, 22].
Information regarding vital status and place of residence of cancer patients
is obtained continuously from the Population Information System
maintained by the Digital and Population Data Services Agency. Causes
of death for cancer patients are received from Statistics Finland once per
year. The FCR has high coverage overall, and in a recent quality study, the
completeness for HL was estimated at 93.4%, and 99.7% of HL cases were
morphologically verified [23, 24].
Patients
Patients diagnosed with incident NLPHL (ICD-O-3 morphology code 9659/
3) in Finland in 1995–2018 were retrieved from the FCR database. Patient
selection was restricted to those diagnosed as of 1995 to ensure a
representative cohort considering that NLPHL was first recognized as a
distinct entity and separated from the cHL subtypes in the revised
European American lymphoma (REAL) classification of 1994 [25, 26]. A total
of 485 patients were initially identified. The diagnosis of NLPHL and
possible transformation were confirmed from the free-text part of the
pathology reports. Clinical reports were used for additional confirmation. In
unclear cases, additional information was requested from the pathology
laboratories. We excluded 11 patients with incorrect registry entries or
missing cancer notifications and 5 patients diagnosed with other
lymphoma before NLPHL. Sixteen patients diagnosed concurrently with
a combination of NLPHL and a large B-cell lymphoma, i.e., composite
lymphoma, were also excluded from the study. Therefore, the study
population consisted of 453 patients. None of the NLPHL diagnoses or
transformations were registered by death certificate or autopsy only.
Incident transformation was defined as the diagnosis of morphologically
verified large B-cell lymphoma or high-grade B-cell lymphoma at least
3 months after the primary diagnosis of NLPHL.
The statistical underlying causes of death for deceased NLPHL patients
were retrieved from Statistics Finland. Causes of death were determined
according to the selection and application rules of the International
Classification of Diseases (ICD-10) compiled by the World Health
Organisation (WHO).
For all NLPHL patients, we collected data on sex; date of birth,
diagnosis of NLPHL, and last follow-up; vital status at the end of follow-
up; possible date of transformation; and cause of death. The study cohort
was followed until December 31, 2018. One patient was lost to follow-up
before the end of the study period. General population mortality rates of
Finland were obtained from Statistics Finland. Cause of death was
categorized into three groups: any lymphoma, secondary malignant
neoplasm, or other cause.
The study was approved by the National Institute for Health and Welfare
(Dnro THL/1441/5.05.00/2019), Statistics Finland (Dnro TK-53-1172-19), and
Helsinki University Hospital Institutional Review Board.
Statistical analysis
The start of follow-up was defined as the date of NLPHL diagnosis. The
Kaplan-Meier method was used to estimate overall survival. A competing
risk method (Aalen-Johansen estimator) was used to estimate the
cumulative incidence of transformation, with death due to other causes
as the competing risk. Hazard ratios (HRs) for death from any cause and
incident transformation were estimated using multivariable Cox regression
models. Age at diagnosis was modeled as a linear continuous variable and
year of diagnosis as a linear continuous or a categorical variable.
Relative survival was estimated using the Ederer II method with internal
age-standardization (age groups: 0−14, 15−44, 45−54, 55−64, 65−74,
and ≥75 years) and monthly intervals for collapsing the data [27].
Complete analysis was based on all person-time and deaths in 1995−2018.
Period analyses were carried out for 1995−2006 and 2007−2018, with left-
truncated data for the later period [28].
To estimate HRs for excess mortality, we used multivariable flexible
parametric survival models [29]. Expected mortality was based on the
general population mortality rates of Finland by 1-year age group, calendar
year, and sex. The baseline excess hazard rate was modeled with 4 degrees
of freedom [30].
When analyzing total and excess mortality, transformation was treated
as a time-varying covariate. To allow for non-proportional hazards, we fit
separate models that also included time from transformation. After
splitting the time scale into monthly intervals, the time-dependent effect
of transformation was modeled with a restricted cubic spline with 2
degrees of freedom.
The Wilcoxon rank-sum test was used to compare age at diagnosis
between groups.
Statistical analyses were performed using R, version 4.0.2 (R Foundation
for Statistical Computing, Vienna, Austria), with the packages survival 3.1-
12, rstpm2 1.5.2, Epi 2.44, and popEpi 0.4.8.
RESULTS
Patients
We identified 453 patients diagnosed with NLPHL in Finland
between January 1995 and December 2018. Baseline character-
istics of the patients, as well as age-specific rates of transformation
and death, are shown in Table 1. The majority of the patients were
males (76%). The median age at diagnosis was 48 years
(interquartile range (IQR), 34−61; range, 5–87). Females were
significantly older than males at the time of diagnosis (median
age, 58 vs. 45 years; p < 0.001). The median follow-up time was 8.1
years (IQR, 3.4−14.1; range, 0‒24 years).
Risk of transformation
Incident transformation occurred in 25 patients during 4059
person-years of follow-up (crude transformation rate, 6.2/1000).
The cumulative incidence of transformation was 3.5% (95% CI,
2.1–5.9) at 5 years and 6.3% (95% CI, 4.2–9.6) at 10 years from
diagnosis, reaching a plateau thereafter (Fig. 1). The majority of
the transformations (22 of 25) occurred within 10 years from
diagnosis; one occurred between 10–19 years and two after 20
years. Of the 25 transformations, 18 (72%) occurred in males. The
median age at the time of transformation was 57 years (IQR,
40–69; range, 27–87). The risk of transformation was not
significantly associated with age at diagnosis (HR, 1.22 per 10-
year increase; 95% CI, 0.94–1.57; p= 0.13), sex (HR, 1.26 for
females compared with males; 95% CI, 0.50–3.18; p= 0.6), or year
of diagnosis (HR, 0.73 per 10-year increase; 95% CI, 0.37–1.43; p=
0.4). In addition, after adjustment for age at diagnosis and sex, we
found no significant association with the period of diagnosis (HR,
0.66 for 2005‒2018 compared with 1995‒2004; 95% CI, 0.29‒1.53,
p= 0.3). The histology at the time of transformation was diffuse
large B-cell lymphoma NOS in 15 patients (60%) and T-cell/
histiocyte rich large B-cell lymphoma in 10 patients (40%).
Overall survival
There were 78 deaths during a follow-up of 4 182 person-years
(crude mortality rate, 18.6/1 000). The overall survival probability
was 85% (95% CI, 81%–89%) at 10 years and 65% (95% CI,
58%–74%) at 20 years from diagnosis.
Among the patients with transformation, 12 died during 123
years of follow-up after transformation. The crude mortality rate
following incident transformation was 97.4/1000 compared with
16.3/1000 among patients without transformation.
After adjusting for potential confounders (age at diagnosis, sex,
and year of diagnosis), transformation was associated with a
substantial increase in total mortality (HR, 8.55; 95% CI, 4.49–16.3;
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p < 0.001) (Table 2). The relative risk of death, as compared with
the patients without transformation, appeared to be highest at the
time of transformation (Fig. 2). The time-dependent HRs at 1, 5,
and 10 years after transformation were 15.0 (95% CI, 7.16‒31.4),
3.38 (95% CI, 0.86‒13.4), and 3.00 (95% CI, 0.79–11.5), respectively.
Relative survival and excess risk of death
In complete analysis (including the entire follow-up in 1995‒2018),
the 10-year age-standardized relative survival was 94% (95% CI,
89%‒100%) (Fig. 3A). In period analysis, the 5-year age-standar-
dized relative survival was 96% (95% CI, 92%‒100%) in 2007‒2018
compared with 89% (95% CI, 83%‒95%) in 1995‒2006 (Fig. 3B).
Adjusted HRs for excess mortality are shown in Table 2. Older
age at diagnosis was associated with increased excess mortality
(HR, 1.75 per 10-year increase; 95% CI 1.15‒2.66; p = 0.009),
whereas patients diagnosed at a later calendar year had lower
excess risk of death (HR, 0.38 per 10-year increase; 95% CI, 0.15‒
0.98; p = 0.046). There was no significant sex difference in excess
mortality. Transformation was associated with a substantial
increase in excess mortality (HR, 26.7; 95% CI, 9.41‒75.9; p <
0.001), but the excess relative risk appeared to decrease over time.
The time-dependent excess HRs at 1, 5, and 10 years after
transformation were 30.7 (95% CI, 12.2‒77.1), 6.79 (95% CI, 1.16‒
39.6), and 7.39 (95% CI, 1.18‒46.1), respectively.
Causes of death
Of the 78 deaths during the study period, 32 (41%) were due to
any lymphoma, 14 (18%) to secondary malignant neoplasm, and
32 (41%) to other causes. Other causes of death were most
frequently related to cardiovascular and infectious diseases. Of the
12 deaths recorded in the patients with incident transformation,
11 (92%) were due to any lymphoma.
DISCUSSION
In this large nationwide, population-based cohort study of the
patients diagnosed with NLPHL in Finland between 1995 and
2018, the risk of transformation was 6.3% at 10 years, resulting in a
substantially increased mortality in comparison to the patients
without transformation. Overall, however, we found that the 10-
year relative survival for the entire study period was excellent. Our
results also suggest a reduction in excess mortality over time and
a slight improvement in 5-year relative survival between 1995-
2006 and 2007-2018. Finally, excess mortality was higher for the
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Fig. 1 Cumulative incidence of transformation. The dashed lines
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The incidence of NLPHL has nearly doubled in some countries
since the 1990s, reaching 2-3/1,000,000 during the 2000s
[5, 15, 31]. Whether this represents a true rise or evolving
diagnostic practice is unclear. In contrast, the incidence of NLPHL
in Finland has remained stable at 3/1,000,000 since the 1990s [7].
One possible explanation may lie in the diagnostic centralization
of rare lymphomas to university hospitals and review of most
cases by hematopathologists in Finland, which is known to
increase diagnostic accuracy [32, 33]. In this study, 80% of cases
were diagnosed in one of five university hospitals or reviewed by
an expert hematopathologist.
The high proportion of males (76%) in our cohort is consistent
with previous studies [8, 15]. The median age of 48 years at
diagnosis is also in line with a population-based study from
Sweden [34]. In addition, we observed that females were
significantly older than males at the time of diagnosis. Interest-
ingly, a study from the United States found approximately equal
proportions of females and males among African American
patients diagnosed with NLPHL [35]. Furthermore, Caucasian
females were more likely to be diagnosed at a later age than
African American females. However, a direct comparison with our
study is not feasible considering differences in ethnical back-
ground between the Finnish and the United States population.
In general, NLPHL is associated with excellent prognosis and
low excess mortality [15, 17, 34, 36]. In the present study, the 10-
year age-standardized relative survival was 94%, which is
consistent with a recently published population-based study from
the Netherlands [15]. In addition, 5-year relative survival improved
slightly between 1995−2006 and 2007−2018. Deaths during the
study period were attributed to any lymphoma (41%), secondary
malignant neoplasms (18%), and other causes (41%). Lymphoma
was a major cause of death in patients with incident
transformation (92%).
The risk of transformation was 6.3% (95% CI, 4.2–9.6) at 10 years,
which is lower than in two other relatively large studies [12, 13]. In
a French registry-based study, the 10-year cumulative risk of
transformation, based on the Kaplan-Meier method, was 12%
(95% CI, 7‒17) with a high biopsy rate at recurrence (85%) [12]. In
a British study, transformation occurred in 26 of 153 patients
(17%), but the risk was not estimated for a specified time interval
[13]. The majority of the previous studies have been limited either
by lack of population-based data collection (single-institution or
pooled multi-center studies), small sample size, short follow-up
time, lack of histological verification of transformation, or inclusion
of composite lymphomas [10, 11, 14, 37–40].
We excluded 16 patients with composite lymphoma from the
study. It is, however, possible that these patients had undiagnosed
NLPHL, which eventually transformed into composite lymphoma.
On the other hand, composite lymphoma may have developed as
a primary neoplasm.
Our results indicated that the risk of death was substantially
higher in patients with transformation compared with patients
without transformation. Considering transformation as a time-
varying covariate avoids immortal time bias, which is a common
problem in the medical literature [41]. A possible explanation for
the decrease in relative risk over time is that patients who have
survived a given length of time after transformation represent a
selected population with less aggressive disease, better treatment
response, or otherwise more favorable prognostic factors than the
complete population of patients with transformation.
Increased age at diagnosis was associated with higher excess
mortality. The use of general population mortality rates as a
reference allows the study of age at diagnosis as a predictor of
disease- or treatment-related mortality, whereas total mortality is
strongly influenced by causes unrelated to NLPHL. Treatment
toxicities may be more frequent among elderly patients, but the
biology of NLPHL could also differ between age groups. There was
no significant association between sex and excess mortality, which
is in accordance with a large study from the Netherlands [15].
However, future population-based studies are warranted to
validate this finding.
Interestingly, we found a significant reduction in excess
mortality for the patients diagnosed with NLPHL during more
recent years. We hypothesize that mortality may have decreased
gradually over time due to a shift toward less aggressive
treatment approaches both in up-front and recurrence settings,
Table 2. Hazard ratios for total and excess mortality in patients with nodular lymphocyte predominant Hodgkin lymphoma.
Characteristic Total mortality Excess mortality
HRa 95% CIb p-value HRa 95% CIb p-value
Age at diagnosis (per 10-year increase) 2.09 1.74−2.52 <0.001 1.75 1.15−2.66 0.009
Sex
Male 1.00 — — 1.00 — —
Female 0.71 0.42−1.22 0.2 0.89 0.29−2.77 0.8
Year of diagnosis (per 10-year increase) 0.52 0.34−0.80 0.003 0.38 0.15−0.98 0.046
Transformation
Nontransformed 1.00 — — 1.00 — —
Transformed 8.55 4.49−16.3 <0.001 26.7 9.41−75.9 <0.001
a HR, hazard ratio





















Fig. 2 Hazard ratio for death (on a logarithmic scale on the y-axis)
by the time from transformation. The dashed lines indicate 95%
confidence intervals.
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including a higher proportion of patients on active surveillance,
the use of less extended radiation fields, and the introduction of
biological agents into treatment regimens. In a population-based
study from Sweden, the use of rituximab increased from 7% to
67% between 2000–2004 and 2005–2014 in the first line
treatment for advanced-stage NLPHL [34]. We expect that
treatment trends in Finland are similar to the other Nordic
countries and follow international guidelines [19]. Furthermore,
higher biopsy rates at recurrence in more recent years could have
resulted in better detection of incident transformations with
adequate treatment given accordingly. However, the risk of
transformation was not associated with the period of diagnosis in
our study. Taken together, these factors may have reduced both
early and late treatment-related mortality over time. Over-
diagnosis is unlikely to explain the decrease in excess mortality
because the incidence of NLPHL remained stable during the
study period.
The strengths of this study are the population-based design and
the use of high-quality nationwide cancer registry data from a
long calendar period of 24 years. Furthermore, all NLPHL
diagnoses and transformations were reviewed from the original
pathology reports at the Finnish Cancer Registry, and 80% of the
cases were diagnosed in one of Finland’s five university hospitals
or reviewed by an expert hematopathologist.
However, some limitations require careful consideration. First,
we could not perform a central pathology review to confirm the
diagnosis of NLPHL. Second, detailed individual-level data on
treatment was unavailable. Although the patients with NLHPL in
Finland are treated according to international guidelines, which
strongly recommend a biopsy confirmation prior to establishing a
diagnosis of histologic transformation, we cannot exclude the
possibility that some patients were treated for presumed
transformation based solely on clinical findings. Third, the FCR
did not have information on stage, performance status, or
comorbidities.
Collectively, our data underscore the importance of long-
term follow-up, re-biopsy at the time of relapse, and minimiza-
tion of the risks for late adverse effects associated with
treatment.
In conclusion, this large population-based cohort study with
long-term follow-up demonstrates excellent long-term relative
survival for patients diagnosed with NLPHL in Finland between
1995 and 2018. Excess mortality was lower among NLPHL
patients diagnosed in more recent years. The risk of transforma-
tion to aggressive B-cell lymphoma was 6.3% at 10 years, and
transformation was associated with a substantially increased risk
of death.
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